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A B S T R A C T
Background
Surgical wounds that become infected are often debrided because clinicians believe that removal of this necrotic or infected tissue will
expedite wound healing. There are numerous methods available but no consensus on which one is most effective for surgical wounds.
Objectives
To determine the effect of different methods of debridement on the rate of debridement and healing of surgical wounds.
Search methods
In March 2013, for this third update, we searched the Cochrane Wounds Group Specialised Register; the Cochrane Central Register
of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed
Citations); Ovid EMBASE; and EBSCO CINAHL.
Selection criteria
We included randomised controlled trials (RCTs) with outcomes including at least one of the following: time to complete debridement
or time to complete healing.
Data collection and analysis
Two review authors independently reviewed the abstracts and titles obtained from the search, extracted data independently using a
standardised extraction sheet and independently assessed methodological quality. One review author was involved in all stages of the
data collection and extraction process, thus ensuring continuity.
Main results
Five RCTs (159 participants) were eligible for inclusion; all compared treatments for infected surgical wounds and reported time
required to achieve a clean wound bed (complete debridement). One trial compared an enzymatic agent (streptokinase/streptodornase)
with saline-soaked dressings. Four trials compared the effectiveness of dextranomer beads or paste with other products (different
comparator in each trial) to achieve complete debridement. Meta-analysis was not possible due to the unique comparisons within each
trial. One trial reported that dextranomer achieved a clean wound bed significantly more quickly than Eusol, and one trial comparing
enzymatic debridement with saline-soaked dressings reported that the enzyme-treated wounds were cleaned more quickly. However,
methodological quality was poor in these two trials.
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Authors’ conclusions
There is a lack of large, high-quality published RCTs evaluating debridement per se, or comparing different methods of debridement
for surgical wounds, to guide clinical decision-making.
P L A I N L A N G U A G E S U M M A R Y
Debridement for surgical wounds
Following surgery most surgical wounds heal naturally with no complications. However, complications such as infection and wound
dehiscence (opening) can occur which may result in delayed healing or wound breakdown. Infected surgical wounds may contain
dead (devitalised) tissue. Removal of this dead tissue (debridement) from surgical wounds is believed to enable wound healing. Many
methods are available to clinicians to debride surgical wounds. This review showed that there is insufficient valid research evidence to
recommend any one particular method.
There is a clear need for more research into which method is most effective in removing dead tissue from surgical wounds that have
become infected.
B A C K G R O U N D
Surgical wounds, by definition, are initially acute and most heal
naturally without delay or complications (Bale 1997; Baxter
2003). However, complications such as infection and wound de-
hiscence (opening) may occur, and may result in either delayed
wound healing or wound breakdown, or both. Wounds with sur-
gical site infections may contain devitalised (dead) tissue. The ap-
pearance, colour and texture of this tissue may vary from hard,
black tissue (necrotic or eschar) to a soft fibrous yellow or green
tissue (slough) (Thomas 1999; Vowden 1999a; Ramundo 2000;
Stotts 2000; O’Brien 2003a). This may be accompanied by in-
creased production of fluid (exudate) and the presence of an odour
(Dealey 1994; O’Brien 2003a).
There is a widely held belief that wound healing is impeded by
the presence of devitalised, necrotic tissue and wounds containing
such material do not heal successfully (Baharestani 1999; Lewis
2000; Stotts 2000; NICE 2001; O’Brien 2002). Non-viable tissue
not only inhibits the growth of epithelial tissue, but also increases
the production of exudate, impairs assessment of the wound bed,
and makes it more difficult to achieve wound closure, thus having
an adverse effect on quality of life (Baharestani 1999). Although
Baharestani 1999 details a number of reasons for the removal of
the dead tissue (as detailed above), these reasons do not appear to
be supported by robust, scientific evidence.
Debridement is the process whereby foreign material and dead or
damaged tissue and debris are removed from a wound (Vowden
1999a; O’Brien 2002; O’Brien 2003c). Debridement of wounds
includes any method that removes infected or contaminated tis-
sue, cell debris or dead, devitalised, fibrous material (frequently
classified as eschar or slough) to create a clean wound bed (Vowden
1999a; NICE 2001; O’Brien 2002). Debridement is thought
to provide a foundation for the subsequent healing of wounds
(O’Brien 2003b).
Debridement may be achieved by a variety of methods including:
surgery; biosurgical (larvae) debridement; autolytic debridement;
mechanical debridement; chemical debridement and enzymatic
debridement.
Surgical or sharp debridement
Surgical debridement may be achieved by the aggressive excision
of all devitalised tissue using surgical techniques (Thomas 1999;
Vowden 1999b; Sibbald 2000; Schultz 2003). Disadvantages as-
sociated with this method are the requirement for hospital admis-
sion, the administration of an anaesthetic with associated compli-
cations, and time in the operating theatre. It is also associated with
pain, bleeding and excision of healthy tissue and, as such, is not
suitable or desirable for all patients (Baharestani 1999; Thomas
1999; Vowden 1999b; Sibbald 2000; Schultz 2003). On the other
hand, sharp debridement involves the excision of small quantities
of dead tissue by a clinician using scissors or a scalpel (O’Brien
2003a; O’Brien 2003c). This procedure may be performed in a
community or hospital setting (Poston 1996). However, for both
surgical and sharp procedures, issues of patient consent, training
and skill of the clinician must be considered (Ashworth 2002).
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Biosurgical/biological debridement
In biosurgical or biological debridement, sterile larvae (maggots)
of the Lucilia sericata species of greenbottle fly are applied to a
sloughy wound. There, the larvae are capable of producing pow-
erful proteolytic enzymes that destroy the dead tissue by lique-
fying and ingesting it. Healthy tissue in the wound bed is not
damaged and, although there are aesthetic considerations, larvae
are increasingly being used for wound debridement (Baharestani
1999; Lewis 2000; O’Brien 2003a).
Autolytic debridement
Over time, naturally occurring enzymeswill eventually break down
and dissolve dead or sloughy tissue inwounds. This natural process
is promoted by the maintenance of a moist environment through
judicious use of dressings and topical agents (e.g. hydrogels, semi-
occlusive and occlusive wound dressings). Many of these dressings
hydrate and remove black, necrotic tissue and slough (Baharestani
1999; Vowden 1999a; Lewis 2000). Dextranomer is an example
of a hydroscopic dressing which has a high absorptive capacity and
is capable of removing bacteria, debris and absorbing wound exu-
date, thereby facilitating autolytic debridement. However world-
wide production of dextranomer beads and paste was discontin-
ued in 2007, with the exception of the paste which is still available
in South Africa.
Mechanical debridement
Mechanical methods of debridement are non-selective and may
result in damage to healthy tissue (Baharestani 1999). These
methods include: wet to dry debridement, wound cleansing de-
bridement andwhirlpool debridement (Vowden 1999a; Ramundo
2000; O’Brien 2003a; Stotts 2004; Falabella 2006).
Wet to dry debridement
The wet to dry method of debridement involves the application
of a saline-soaked gauze dressing to a wound. The moist dress-
ing induces separation of the devitalised tissue and, once dry, the
dressing is removed, together with the slough and necrotic tissue.
This process is continued until all the devitalised tissue is removed.
This is reported to be a painful procedure andmay damage healthy
tissue; fibres may be left in the wound and the dressing does not
provide a barrier to bacterial contamination (Baharestani 1999;
Ramundo 2000; O’Brien 2003a; Stotts 2004).
Wound cleansing debridement
Wound cleansing debridement involves irrigating a wound with
a continuous or intermittent flow of fluid delivered under high
pressure. The force of the fluid is between 8 and 12 pounds per
square inch (psi), and is sufficient to remove devitalised tissue
and wound bacteria (Baharestani 1999; Ramundo 2000). Newer
wound cleansing systems use pressurised saline delivered via a noz-
zle at between 12,800 and 15,000 psi (Granick 2006).
Whirlpool debridement
Whirlpool debridement is used for large wounds on the trunk or
extremities. The affected person is immersed in a whirlpool bath,
where the vigorous action of the water and its hydrating effect
loosen the surface bacteria and devitalised tissue, and allow them
to be washed away (Baharestani 1999; Ramundo 2000).
Chemical debridement
A range of chemical agents, including hypochlorites such as EU-
SOL (Edinburgh University Solution of Lime) and Dakin’s Solu-
tion (sodium hypochlorite), hydrogen peroxide and iodine, have
beenused topromote debridement ofwounds. The use of chemical
agents remains a controversial area, in which any benefits need to
be judged against any detrimental effects on the process of healing
(Brennan 1985; Baharestani 1999; Hofman 2002; Ayello 2004).
Enzymatic debridement
Topical enzymatic preparations are applied to moist (or moist-
ened) devitalised tissue. Such preparations include: streptoki-
nase/streptodornase (Lewis 2000; O’Brien 2003a), collagenase
(Ramundo 2000; Stotts 2004), papain/urea, and a combination of
fibrinolysin anddeoxyribonuclease (Ramundo 2000; Stotts 2004).
This method has a number of disadvantages, including a require-
ment for frequent dressing changes and a slow rate of debridement.
Worldwide production of the enzymatic preparation of streptok-
inase/streptodornase has now been discontinued.
Overview
There is considerable debate about the appropriateness and efficacy
of debridement methods (Ashworth 2002). A systematic review
published in 1999 indicated that there were no studies comparing
non debridement with debridement and therefore the benefits of
debridement on wound healing were unclear (Bradley 1999). A
guidance document on the use of debriding agents for difficult-
to-heal surgical wounds highlighted the lack of sufficient evidence
(and the corresponding absence of randomised controlled trials
(RCTs)) to support any particular method of debridement (NICE
2001). However a Cochrane Review on the debridement of dia-
betic foot ulcers found evidence suggesting that the rate of healing
increased when a hydrogel dressing was used in comparison to
a gauze dressing (Edwards 2010). The choice of debriding agent
and method is usually made on the basis of the clinician’s expertise
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and knowledge, the available resources and cost (Flanagan 1999).
Since wound management choices, however, continue to increase,
as do the cost of products, the choice of debridement method or
agent should be guided by good evidence (Lewis 2000). An up-to-
date review of debridement for surgical wounds is therefore nec-
essary, to enable evidence-based clinical decision-making.
O B J E C T I V E S
To determine the effects of different debriding methods on the
rate of debridement and healing of surgical wounds.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs evaluating debridement in themanagement
of surgical wounds.
Types of participants
We included studies on people of any age, in any care setting, with
a surgical wound that required debridement, but excluded studies
of wounds that were not caused by surgery (i.e. trauma wounds,
burns, abscesses or sinuses, pressure ulcers, leg ulcers, diabetic foot
ulcers, fungating tumours and wounds caused by the removal of
foreign bodies).
Types of interventions
We considered any method of debridement compared with a con-
trol regimen (a placebo, an alternative method of debridement,
any other therapy or no treatment) including:
• surgical, such as the excision of all devitalised tissue, or
sharp, such as the excision of small quantities of non-viable tissue
using a scalpel or scissors;
• biosurgical, such as the use of sterile larvae;
• autolytic, such as the use of hydrogels/hydrocolloids to
promote a moist environment;
• mechanical, such as wet to dry debridement, high-pressure
irrigation or whirlpool debridement;
• chemical, such as the use of Eusol or Dakin’s Solution; and
• enzymatic debridement, such as topical enzymatic
preparations (e.g. collagenase).
Types of outcome measures
A trial report had to provide at least one of the primary outcomes
to be included in the review.
Primary outcomes
• Time to complete debridement.
• The proportion of wounds completely debrided during the
trial period.
• The rate of reduction in wound size expressed in either
absolute or relative terms.
• The proportion of wounds completely healed during the
trial period.
• Time to complete healing.
Secondary outcomes
When reported, we recorded the following secondary outcomes:
• patient satisfaction (e.g. pain associated with treatment as
recorded using a recognised pain scale);
• rate of infection;
• quality of life;
• length of hospital stay;
• cost-effectiveness (e.g. as presented in a cost-effectiveness
analysis, which may include: nursing time; time taken to change
dressing; number of dressing changes required; cost of dressing
materials);
• serious adverse events (life-threatening or those leading to
hospitalisation);
• other adverse events (those leading to discontinuation of
treatment).
Search methods for identification of studies
The searchmethods used in the second reviewupdate can be found
in Appendix 1.
Electronic searches
In March 2013, for this third update, we searched the following
databases for reports of eligible trials:
• the Cochrane Wounds Group Specialised Register (searched
28 March 2013);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2013, Issue 2);
• Ovid MEDLINE (2011 to March Week 2 2013);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, March 26, 2013);
• Ovid EMBASE (2011 to 2013 Week 12); and
• EBSCO CINAHL (2011 to 22 March 2013).
We used the following strategy in the Cochrane Central Register
of Controlled Trials (CENTRAL):
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#1 MeSH descriptor Debridement explode all trees
#2 debrid*
#3 MeSH descriptor Larva explode all trees
#4 (larva* or maggot* or biosurgery or bio-surgery)
#5 wound* NEXT irrigat*
#6 wound* NEXT cleans*
#7 whirlpool
#8 collagenase* or fibrinolytic* or proteolytic* or trypsin or strep-
tokinase or streptodornase or varidase
#9 hypochlorite or hydrogen NEXT peroxide
#10 malic NEXT acid or benzoid NEXT acid or salicylic NEXT
acid or propylene NEXT glycol
#11 dakin solution
#12 dextranomer* or cadexomer or xerogel or eusol or debrisan
#13 polysaccharide NEXT bead* or polysaccharide NEXT paste*
#14 iodoflex or iodosorb
#15 intrasite NEXT gel or intrasitgel or sterigel or granugel or
nugel or purilon NEXT gel or purilon or vigilon
#16 gauze NEXT dressing* or adherent NEXT dressing* or ab-
sorbent NEXT dressing* or tulle NEXT dressing* or polysaccha-
ride NEXT dressing* or hydrofibre NEXT dressing* or “wet to
dry dressing” or “wet to dry dressings”
#17 hydrocolloid* or granuflex or tegasorb or aquacel or hydrocoll
or combiderm or duoderm
#18 alginate NEXT dressing* or foam NEXT dressing* or hydro-
gel* or saline NEXT gauze
#19 MeSH descriptor Honey explode all trees
#20 honey*
#21 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20)
#22 MeSH descriptor Surgical Wound Infection explode all trees
#23 MeSH descriptor Surgical Wound Dehiscence explode all
trees
#24 surg* NEAR/5 infection*
#25 surg* NEAR/5 wound*
#26 (postoperative or post-operative) NEAR/5 infection*
#27 exudat* NEAR/5 wound*
#28 exudat* NEAR/5 cavit*
#29 necrot* NEAR/5 wound
#30 necrot* NEAR/5 cavit*
#31 (#22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28
OR #29 OR #30)
#32 (#21 AND #31)
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 2; Appendix 3 and
Appendix 4 respectively.We combined theMEDLINE searchwith
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format (Lefebvre 2011). We
combined the EMBASE and CINAHL searches with the trial fil-
ters developed by the Scottish Intercollegiate Guidelines Network
(SIGN 2007). There were no restrictions with respect to language,
date of publication or study setting.
Searching other resources
We contacted manufacturers of wound products by e-mail for
details of published, unpublished and ongoing trials (Smith &
Nephew Healthcare Ltd; Convatec Ltd; Johnston & Johnston;
Medihoney). To date we have identified no new citations for this
review through these contacts. We checked the citations within
obtained studies to identify additional papers.
Data collection and analysis
Selection of studies
Two review authors (ND and FS) independently assessed for rele-
vance and design the titles and abstracts of studies identified. They
obtained full versions of articles that met the inclusion criteria of
this initial assessment. A third review author (MM) was consulted
for adjudication on some abstracts. All rejected titles and abstracts
were reviewed by (MM).
Data extraction and management
We used a standardised extraction sheet to record and summarise
details of the studies. Two review authors (ND and JD) indepen-
dently performed data extraction. Discrepancies were resolved by
discussion and referred to a third review author (FS).
We extracted the following data:
• general information: author(s), title, source, contact
address, year of study, country of study, language of publication,
year of publication;
• trial characteristics: design (RCT), randomisation method,
manner of recruitment, sampling method, duration of
intervention period, length of follow up, reason for and number
of dropouts and withdrawals, adverse events;
• participants: baseline characteristics such as sex, age, type of
wound, wound size, duration of wound, method of
debridement, prevalence of co-morbidities (e.g. diabetes), study
inclusion and exclusion criteria, all by treatment group;
• intervention: detailed description of the comparison
dressing/method, co-interventions, duration;
• outcome measures;
• primary outcomes: time to complete debridement,
proportion of wounds completely debrided, reduction in wound
size, proportion of wound completely healed, time to complete
healing;
• secondary outcomes: patient satisfaction (pain assessment),
rate of infection, quality of life, length of hospital stay, cost-
effectiveness, serious/other adverse events;
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• any co-interventions; and
• where trials were sponsored by the dressing manufacturer.
Assessment of risk of bias in included studies
For the update of this review we assessed each included study for
risk of bias, without blinding to journal or authorship, using the
Cochrane Collaboration tool (Higgins 2011). This tool addresses
six specific domains, namely sequence generation, allocation con-
cealment, blinding, incomplete outcome data, selective outcome
reporting and other issues (e.g. extreme baseline imbalance) (see
Appendix 5 for details of the criteria on which the judgements
were based). We assessed blinding and completeness of outcome
data for each outcome separately. We completed a ’Risk of bias’
table for each eligible study.
We presented an assessment of risk of bias using a ’Risk of bias’
summary figure (Figure 1 and Figure 2), which presents all of the
judgements in a cross-tabulation of study by entry. This display of
the internal validity indicates the weight the reader may give the
results of each study. We classed studies as being at high risk of
bias overall if any one of the criteria were judged to be at high risk
of bias.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
7Debridement for surgical wounds (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Assessment of heterogeneity
Should data be available in future updates, we will explore both
clinical and statistical heterogeneity. In the absence of clinical and
statistical heterogeneity we will apply a fixed-effect model to pool
data, if appropriate. In the presence of statistical heterogeneity (as
estimated by the I² statistic where values of I² over 75% indicate
a high level of heterogeneity) (Higgins 2003) we will apply a ran-
dom-effects model for meta-analysis. Where synthesis is inappro-
priate we will undertake a narrative overview. If there are any cost-
effectiveness data then these will be summarised narratively.
Data synthesis
Where appropriate datawere entered intoRevMan5 by one review
author (ND) and checked by two others (JD) and (FS). We con-
verted continuous data (e.g. total area healed, or changes in vol-
ume of ulcers) to the standardised mean difference (or a weighted
mean difference, when plausible) and calculated overall effect size
(with 95% CI). We analysed time to wound healing and time to
return to work as survival (time to event) data, using the appropri-
ate analytical method (as per theCochrane Handbook for Systematic
Reviews of Interventions version 5.0 (Higgins 2011)).
Subgroup analysis and investigation of heterogeneity
Should data be available in future updates, we may use subgroup
analysis to investigate the effect of pre-existing pathology (e.g.
diabetes), or ages of subjects (e.g. below or above age 14 years), or
location of wound (e.g. abdominal, thoracic wounds) on surgical
wound debridement.
R E S U L T S
Description of studies
None of the titles or abstracts (425 citations) retrieved in the up-
dated search were relevant to this review.
Our original 2008 search identified 2087 titles and abstracts. A to-
tal of 30 abstractswere potentially relevant andwe obtained the full
publications of these. Five of these publications were in languages
other than English and after translation it was apparent that only
one of these was a RCT. Two authors (ND and MM) indepen-
dently read the publications and applied the inclusion and exclu-
sion criteria. They made referral to a third author (JD) regarding
three trials. Six RCTs were initially identified as having met the in-
clusion criteria (see ’Characteristics of included studies’ table); the
randomisation status of one was unclear and the author did not re-
spond to requests for further information (Zeitani 2004) therefore
we excluded this trial (see ’Characteristics of excluded studies’ ta-
ble), leaving five included trials (Goode 1979; Sondergaard 1982;
Young 1982; Poulson 1983; Michiels 1990). All identified trials
were published between 1979 and 1990; trial sizes ranged from
18 to 50 participants and, where reported, ages ranged from three
years to 91 years. Small sample size was the main deficiency of the
five trials and none of the trials reported an a priori sample size
calculation.
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All the trials compared treatments for infected post surgical
wounds and, although the term debridement was mentioned in
only one of the five trials(Michiels 1990), each trial reported the
time required to obtain a clean wound bed. As the debridement
of wounds includes any method that removes infected or contam-
inated tissue, cell debris or devitalised material to create a clean
bed, we considered the five trials eligible for inclusion in the re-
view. The five trials entered people with post surgical wounds all
described as infected, or at risk of infection, and reported that the
wounds were either left open, or required opening and drainage
for infection. Reporting of the type and site of the surgery and
extent of the wound was variable. Poulson 1983 provided the
most detailed breakdown of the type of surgery performed and
inclusion criteria indicating the minimum length and depth of the
wounds. Sondergaard 1982 reported inclusion of wounds involv-
ing the subcutaneous tissue and Young 1982 included wounds left
open from the muscle layer outwards. Exclusion criteria was not
reported in the trials by Goode 1979and Young 1982.
Four of the trials evaluated the effectiveness of dextranomer
beads or paste in providing a clean wound bed. One com-
pared the effectiveness of dextranomer with Eusol-soaked dress-
ings (Goode 1979). Michiels 1990 compared dextranomer paste
with 10%aqueous polyvinylpyrrolidone.Dextranomer beadswere
compared with 0.1% chloramine soaked packs in the trial by
Sondergaard 1982 and with a polymer foam dressing in another
trial (Young 1982). One trial compared the enzyme prepara-
tion of streptokinase/streptodornase with saline-soaked dressings
(Poulson 1983). Time to a clean wound bed was reported in all
trials and was the primary outcome prior to wound closure or dis-
charge fromhospital (Goode 1979; Poulson 1983;Michiels 1990).
Time to complete healing was reported in two trials (Sondergaard
1982; Young 1982).
Small sample size was the major deficiency of the five trials. The
sample sizes ranged from 18 to 50.
Risk of bias in included studies
We classified studies as being at high risk of bias overall if any
of the following four criteria were judged to be at high risk of
bias: randomisation sequence generation, allocation concealment,
blinding and incomplete outcome data addressed.
All five included trials (Goode 1979; Sondergaard 1982; Young
1982; Poulson 1983; Michiels 1990) were classified as ’unclear’
for the majority of the four key criteria (see ’Risk of bias’ tables for
each study).
Allocation
Adequacy of the randomisation process
All studies reported that allocation was randomised but the
method of generating the randomisation sequence was not always
clear. We judged sequence generation to be adequate in two stud-
ies: Michiels 1990 reported the use of a randomisation list and
Sondergaard 1982 randomised patients in blocks of four. Hence,
we judged these two studies to be at low risk of bias for this domain.
We judged the remaining three studies as at unclear risk of bias as
they did not report sufficient information to make a judgement
with respect to the method of sequence generation: Goode 1979
and Young 1982 used a randomised card system, whilst Poulson
1983 arranged for the hospital pharmacy to control the randomi-
sation but none of them stated how the sequence was generated.
Adequacy of allocation concealment
Two studies reported adequate allocation concealment and were
judged to be at low risk of bias for this domain. Poulson 1983
reported that the hospital pharmacy prepared and provided the
ampoules of the treatment and control solutions (treatment and
control solutions were both 20ml vials of clear fluid). Sondergaard
1982 reported the use of numbered sealed envelops which, al-
though not described as opaque, we have judged it to be adequate
allocation concealment. The extent of the allocation concealment
in the remaining trials was unclear either because insufficient in-
formation was provided or studies did not state that allocation was
concealed.
Blinding
Blinding of outcome assessors
Studies were regarded as at lower risk of bias if the outcome asses-
sor was blinded to the intervention. Only one trial (Goode 1979)
reported that the outcome assessor was blinded to treatment and
the assessment was carried out using photographs rather than a vi-
sual inspection. The remaining trials did not report if the outcome
assessors were blinded and were judged as at unclear risk of bias
for this domain (Sondergaard 1982; Young 1982; Poulson 1983;
Michiels 1990).
Blinding of participants and personnel
None of the included studies reported blinding of participants or
personnel involved in the care of the participants. It would be
difficult to blind the personnel involved in applying the wound
dressings where the control and treatment dressings had very dif-
ferent properties; the same would apply to the participants. It is
reasonable to argue that blinding of these two would not adversely
influence the outcomes measured within the trials, however the
judgement remains as at unclear risk of bias.
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Incomplete outcome data
Goode 1979 and Young 1982 do not record any withdrawals or
dropouts and the number of participants included at the start of
each trial is reflected in the results and therefore were judged to
be at low risk of bias for this domain. Two studies were classified
to be at high risk of bias for this domain: Poulson 1983 reported
three withdrawals which were excluded from the final analysis and
Sondergaard 1982 reported six withdrawals and in the tables of
results indicated that these participants were excluded. It is not
clear if these were also excluded from the final analysis. Also, the
dropout rate in Sondergaard 1982 was 21% (we originally prespec-
ified greater than 80%) and hence was judged to be unacceptable.
The remaining trial reported limited information and was judged
to be ’unclear’ for risk of bias in this domain (Michiels 1990).
Selective reporting
No study protocols were available. However, we judged Goode
1979, Michiels 1990 and Young 1982 to be at low risk of bias
for this domain because they adequately reported the expected
study outcomes. We judged Sondergaard 1982 and Poulson 1983
’unclear’ due to poor reporting.
Effects of interventions
Comparison 1: Dextranomer beads compared with
Eusol gauze (one RCT, 20 participants)
Goode 1979 compared dextranomer beads (an autolytic debride-
ment agent)withEusol-soaked ribbon gauze in 20patientswith in-
fected surgical wounds, following appendectomy or bowel surgery.
Primary outcomes
• Outcome 1 - Time to a clean wound bed and secondary
wound closure:
Resolution of erythema and oedema, absence of pus or slough and
the formation of granulation tissue, were used as the criteria to
determine a clean wound bed. Mean time to a clean wound bed
was significantly shorter with dextranomer; 8.1 days compared
with 11.6 days for Eusol (P < 0.05, Mann-Whitney U-test).
• Outcome 2 - Time to complete healing:
The time to complete healing was not reported, although the tri-
alists report that one wound in each group healed without sec-
ondary closure.
Secondary outcomes
• Outcome 1 - Patient satisfaction: not reported.
• Outcome 2 - Rate of infection: not reported.
• Outcome 3 - Quality of life: not reported.
• Outcome 4 - Length of hospital stay:
Patients in the dextranomer group were described as having a
shorter stay by a median of 2.2 days than the Eusol group, however
no data for the control group were reported.
• Outcome 5 - Cost-effectiveness: not reported:
Goode 1979 commented on the higher cost of dextranomer (£3.40
per twice-daily dressing) but that the shorter hospital stay in the
treatment group compensated for this. This claim was not sup-
ported by any data.
While Goode 1979 demonstrated methodological adequacy in
allocation concealment and blinding of outcome assessment, an
unclear randomisation process, a small sample size and insufficient
data mean it is difficult to place much weight on these results.
Furthermore the comparator (Eusol) is rarely used due to fears of
harmful effects on healthy tissue (Morgan 1991; Morgan 2004).
Comparison 2: Dextranomer paste compared with
10% aqueous polyvinylpyrrolidone (one RCT, 40
participants)
Michiels 1990 compared dextranomer paste with gauze dress-
ings soaked in 10% aqueous polyvinylpyrrolidone (an iodine-
based chemical debridement agent) in people with infected sur-
gical wounds following osteosynthesis, microsurgery and recon-
structive procedures.
Primary outcomes
• Outcome 1 - Time to clean wound bed:
The disappearance or resolution of erythema, pus and debris,
oedema, necrotic tissue and the presence of granulation tissue were
used as the criteria to determine a clean wound bed. The results
for each variable were assessed subjectively and presented individ-
ually. The development, validity and reliability of the assessment
systems used was not reported, but the trialists did acknowledge
that the evaluation was an approximation. The trial reported no
significant difference between the treatment and control groups
for the resolution of erythema, oedema, necrotic tissue and the
development of granulation tissue. The handling and reporting of
the data for the pus and debris criteria were unclear and subjective
and the groups were not comparable at baseline with respect to
the amount of pus and debris. Michiels 1990 reports that dextra-
nomer significantly reduced the time taken to clean the wound bed
compared with polyvinylpyrrolidone. A P value of less than 0.05
was reported (Student’s t-test), however no data were provided,
the outcome was subjective and the outcome assessment was not
reported as masked to treatment.
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• Outcome 2 - Time to complete healing:
The duration of the trial was 12 days and treatment was discon-
tinued when the wound was clean and had new granulation tissue.
Time to complete healing was not reported.
Secondary outcomes
No secondary outcomes were reported in this trial.
The methodological quality of this trial was poor with only the
completeness of follow up adequate. The validity of the results is
questionable.
Comparison 3: Streptokinase/streptodornase
compared with saline-soaked dressing (one RCT, 21
participants)
One small randomised trial compared enzymatic debridement
with streptokinase/streptodornase with saline-soaked dressings in
people with infected abdominal surgical wounds following a range
of operations (Poulson 1983).
Primary outcomes
• Outcome 1 - Time to clean wound bed:
The trial reported the number of days required for a clean wound
bed and secondary suture. Statistical analysis of the data demon-
strated that time to a clean wound bed or secondary suture was
significantly shorter for the streptokinase/streptodornase group
(mean 5 days (SD 2.16)) compared with the saline-soaked dress-
ings group (mean 13.45 days (SD 6.77), P < 0.05 by both Stu-
dent’s t-test and Mann-Whitney U-test). Time to clean wound
bed was analysed using the Student’s t-test and Mann Whitney
U-test. Time to debridement or discharge of the patient are time
to event outcomes and so the treatment effect should have been
expressed as a hazard ratio.
• Outcome 2 - Time to complete healing not reported.
Secondary outcomes
• Outcome 1 - Patient satisfaction: not reported.
• Outcome 2 - Rate of infection: not reported.
• Outcome 3 - Quality of life:
The trial reported that no patients in either group complained of
significant discomfort from the wound.
• Outcome 4 - Length of hospital stay:
Patients in the streptokinase/streptodornase group were described
as having a had a shorter stay by 8.5 days than the saline-soaked
dressings group, however no data or statistics were included in the
trial report.
• Outcome 5 - Cost-effectiveness: not reported.
Methodological adequacy is reported in the randomisation pro-
cess, allocation concealment, blinded outcome assessment and
completeness of follow up. However, poor handling and analysis
of the data and a small sample size are deficiencies in this trial. The
validity of the results is therefore questionable.
Comparison 4: Dextranomer beads compared with
0.1% chloramine-soaked dressings (one RCT, 28
participants)
Sondergaard 1982 randomised 28 patients with infected open sur-
gical wounds to the dextranomer or 0.1% chloramine group.
Primary outcomes
• Outcome 1 - Time to clean wound bed:
The number of days until the wounds were clinically clean were
reported as a median of six days with dextranomer and five days
with chloramine-soaked dressings (described as no significant dif-
ference, however no data provided). The criteria used to determine
when the wound was clinically clean were not reported.
• Outcome 2 - Time from the start of the treatment until the
patient was assessed as ready for outpatient treatment:
This was reported as a median of nine days for dextranomer and
seven days for chloramine; the difference between the two groups
was reported as not significant, however no variance data were
reported.
• Outcome 3 - Time to complete healing:
The time to complete healing was reported as a median of 27 days
for the dextranomer group and 20 days for the chloramine group
(no variance data provided). This was described by the trialists as
no significant difference between the groups.
Secondary outcomes
• Outcome 1 - Patient satisfaction:
The trialists reported that the dextranomer dressing was less
painful as it was easier to remove.However, no data were included.
• Outcome 2 - Rate of infection: not reported.
• Outcome 3 - Quality of life: not reported.
• Outcome 4 - Length of hospital stay: not reported.
• Outcome 5 - Cost-effectiveness:
The average cost per change of dressing for the dextranomer group
was 123 Danish Kroner compared with approximately 1.50 Dan-
ish Kroner for the chloramine group, however no further cost anal-
ysis was reported.
Methodological quality was poor and none of the adequacy criteria
were met by this trial.
11Debridement for surgical wounds (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 5: Dextranomer beads compared with
elastomer foam (one RCT, 50 participants)
Young 1982 randomised 50 people with open, infected surgical
wounds between treatment with dextranomer beads and a foam
elastomer dressing.
Primary outcomes
• Outcome 1 - Time to clean wound bed: not reported.
• Outcome 2 - Time to complete healing:
There was no statistically significant difference in mean time to
healing (40.92 days (SD = 3.98) with dextranomer compared with
36.90 days (SD = 3.18) for elastomer foam). Time to clean wound
bed was analysed as continuous data, using the Student’s t-test (P
> 0.05). Time to a clean wound bed is a time to event outcome
and so the treatment effect should have been expressed as a hazard
ratio.
Secondary outcomes
• Outcome 1 - Patient satisfaction:
The trialists reported that comfort of the dressing was assessed by
questioning the patient. Pain of the wound was graded and the
mean time to a pain-free wound was reduced with dextranomer
at 5.32 days (SD = 0.55) compared with 5.64 days (SD = 0.45)
for foam. Once again the analysis of the data of time to a pain-
free wound should have been expressed as a hazard ratio.
• Outcome 2 - Rate of infection: not reported.
• Outcome 3 - Quality of life: not reported.
• Outcome 4 - Length of hospital stay: not reported.
• Outcome 5 - Cost-effectiveness:
Young 1982 discussed the cost of the dressings reporting that dex-
tranomer was markedly less cost-effective than elastomer foam.
However, no cost analysis data was included and only approxi-
mate costings from another dextranomer trial byGoode 1979 were
quoted.
The trial is poorly conducted and fails to meet the methodological
quality criteria. Poor handling and analysis of the data and a small
sample size are deficiencies in this trial. The validity of the results
presented is therefore questionable.
It was not possible to undertake any subgroup analyses.
D I S C U S S I O N
Despite the availability of a range of debridement methods (see
Background) and an increasing number of modern dressings,
we identified only five poor-quality randomised controlled trials
(RCTs), all conducted prior to 1990.Twomethods of debridement
were employed in the included studies: autolytic debridement us-
ing dextranomer and enzymatic debridement using streptokinase/
streptodornase. It is important to note that no trials were identified
by the search that compared debridement with no debridement
of surgical wounds. This reflects earlier findings by Bradley 1999
and apart from the findings of Edwards 2010, who showed that
the rate of healing of diabetic foot ulcers increased with a hydrogel
dressing when compared with gauze, this review of the evidence
would indicate that there is still little evidence to support the be-
lief that debridement promotes wound healing. Also the merit of
using gauze as a comparator could be questioned, as Pollard 2008
would argue that most, if not all modern dressings would demon-
strate improvement in healing when compared with gauze. How-
ever, in contrast Ubbink 2006 found that time to complete wound
healing was similar when comparing occlusive with gauze-based
dressings for surgical wounds. It is beyond the scope of this review
to postulate reasons for the lack of trials comparing debridement
with no debridement: perceived ethical considerations may be a
barrier to the conducting of such RCTs.
Although only five RCTs conducted prior to 1990 met the inclu-
sion criteria for this review, a range of more recent research papers
were identified but following closer scrutiny were all excluded (see
’Characteristics of excluded studies’ table). It is apparent from these
excluded studies that a range of debridement methods are being
used in clinical practice, including surgical debridement (Zeitani
2004) and mechanical debridement (Allie 2004; Granick 2006),
however these studies are not RCTs and therefore are highly sus-
ceptible to selection bias. It is disappointing that recently pub-
lished studies are not employing more rigorous research methods
that aim to minimise bias and therefore increase the confidence
with which we can view the findings. The cost of conducting a
RCT may be one consideration. Manufacturers of existing and
new wound debridement products appear to use controlled trials,
retrospective analysis of patient case notes and case studies as evi-
dence of effectiveness.
The common outcome for the five included trials was time to a
clean wound bed for infected post surgical wounds. Three out
of the four trials comparing dextranomer with other products re-
ported shorter time to a clean wound bed for dextranomer. The
trial comparing streptokinase/streptodornase with saline dressings
reported a shorter time to a clean wound bed with streptokinase/
streptodornase.
However, a number of trial deficiencies reduce the confidence by
which we can draw any conclusions to inform practice. These
deficiencies include:
1. poor quality of the trials;
2. small sample sizes;
3. limited range of treatments;
4. different control groups for each trial;
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5. lack of replication studies; and
6. inappropriate statistical analysis (time to event data not
being analysed as such).
The methodological quality of the trials was variable, with small
sample sizes, method of randomisation not always being clear, and
inadequate allocation concealment. Data and statistical informa-
tion were incomplete in three of the five trials. Blinding of the
independent assessors would have been possible, but this was only
clearly demonstrated in two studies (Goode 1979; Poulson 1983).
A limited range of treatments was identified with dextranomer
beads or paste and different comparisons used in each trial, there-
fore it was not possible to pool the results. The rationale for choos-
ing dextranomer for the treatment groupswas not clear, apart from
in Young 1982, who identified this as a new dressing, the trial be-
ing supported financially by the manufacturer. Dextranomer was
significantly better than Eusol-soaked dressings (Goode 1979) but
this result must be viewed with caution, as there were insufficient
statistical data included in the small trial andmethodological flaws
in the trial. As worldwide production of dextranomer products
has been discontinued, except for dextranomer paste (which is
currently only available in South Africa), the impact on clinical
practice of these findings is extremely limited.
The enzymatic agent streptokinase/streptodornase demonstrated
a statistically significant reduction in the time to a clean wound
bed when compared with saline-soaked dressings. Poor handling
and analysis of the data was a limitation of this trial and it should
be noted that this enzyme is no longer available worldwide.
There is a complete absence of adequately powered, methodolog-
ically robust RCTs evaluating contemporary debridement inter-
ventions for surgical wounds. The trials included in this review
investigate treatments that are no longer available and the trials
were of poor quality. Trials reflecting the wider range of surgi-
cal, biosurgical, mechanical, chemical and autolytic debridement
methods, and agents for surgical wounds were not identified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Existing RCTs of methods of debridement for surgical wounds are
small, evaluate outdated products and are of poor methodological
quality. Currently there is no RCT evidence to support any par-
ticular debridement method or agent for surgical wounds.
Implications for research
Current innovations in wound debridement strategies increase
the options available to the practitioner. Adequately powered,
methodologically robust RCTs evaluating contemporary debride-
ment interventions for surgical wounds are needed to guide clin-
ical decision-making. Future trials should compare current de-
bridement methods, for example surgical debridement compared
to high-powered saline jet (at high pressure up to 15,000 pounds
per square inch) or honey compared with low-cost established al-
ternatives such as hydrogel dressings. These studies should: report
time to healing as well as time to a clean wound bed; use valid
measures of wound healing; assess quality of life; cost-effectiveness
and be reported in accordance with CONSORT requirements.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Goode 1979
Methods RCT
Setting: hospital and outpatients, UK




Age: 24 to 91 years
Post surgical wounds, infected wounds left open for delayed closure, or closed wounds
requiring opening and drainage following infection
Inclusion criteria: patients at risk from wound infection, following abdominal surgery
for appendicitis or bowel surgery; wounds heavily contaminated at surgery and left open
for delayed primary closure; wounds closed at surgery but developed an abscess and
required removal of sutures and wound drainage
Exclusion criteria: none listed
Interventions All patients were given antibiotic cover prior to surgery for 48 to 72 hours postoperatively
Each wound was photographed at the start, during and at the end of the trial
(A) Twice daily dressings of dextranomer granules covered with a light pack
(B) Twice daily dressings of Eusol and paraffin-soaked ribbon gauze
All other wound procedures were identical for both groups
Independent assessor decided when the wound was clean and could be closed by sec-
ondary suture
Outcomes Primary outcomes:
(1) Mean time to wound closure (SD not reported):
(A) 8.1 days
(B)11.6 days
Statistical difference P < 0.05 (Mann-Whitney U-test)
(2) Time to complete healing not reported
Secondary outcomes:
(1) Patient satisfaction: not reported
(2) Rate of infection: not reported
(3) Quality of life: not reported
(4) Length of hospital stay (median):
(A) 2.2 days less than group B
(B) Not reported
(5) Cost-effectiveness:
(A) Approximately £3.40 per day
(B) Not reported
(6) Adverse events: not reported
Notes Trial did report that 1 patient in each group was left to heal by granulation but the time
to healing was not reported
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Goode 1979 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...each patient was allocated to treatment
with either Debrisan or Eusol by means of
cards drawn from a sealed envelope” (p325)
. However, the method used for generating
the randomisation sequence for the cards
was not reported. Hence, it was judged to
be unclear
Allocation concealment (selection bias) Unclear risk Although “sealed envelopes” are docu-
mented no further details are given
Blinding (performance bias and detection
bias)
Participants and personnel
Unclear risk Participants - blinding not stated but lack
of blinding unlikely to influence results
Personnel - blinding not stated but unlikely
to be achievable due to different properties
(beads versus ribbon gauze). Lack of blind-
ing unlikely to influence results
Blinding (performance bias and detection
bias)
Outcome assessors
Low risk Outcome assessor - blinded to treatment
“an independent assessor decided when the
wound was clean” using photographs of the
wound (p325)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20 patients studied, 20 patients “mean time
to secondary wound closure reported” re-
ported within table 1 (p325). One patient
in each treatment group did not achieve
wound secondary wound closure
Selective reporting (reporting bias) Low risk No study protocol available but expected
outcomes reported
“Efficacy of treatment assessed by time
taken to allow secondary skin closure, by
the condition of the wound after closure
and the number of days in hospital” (p328)
all reported on although limited details
given for the later 2
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Participants n = 40
(A) 20 (10 men, 10 women)
(B) 20 (10 men, 10 women)
Age: 3 to 89 years
Infected post surgical wounds, oozing, covered in pus and debris
Patients all gave informed consent
Inclusion criteria: patients hospitalised in the surgical unit presenting with infected
postoperative wounds, covered in pus and debris
Surgery: ranged from osteosynthesis, microsurgery, reconstructive procedures; surgical
site not reported
Exclusion criteria: patientswith diabetes, vascular insufficiency, severe anaemia and serum
albumin less than 30 g/L
Interventions Duration of the trial was 12 days
(A) Dressing changed daily: wound cleansed - no details of the technique given; a saline-
soaked compress was applied and this was covered by a 3 mm layer of dextranomer paste,
covered with a compress and bandaged
(B) Dressing changed daily; wound cleansed; then a gauze dressing soaked in 10%
aqueous polyvinylpyrrolidone was applied, covered with a dry dressing and bandaged
Further changes of the dressings for groups A and B were dictated by the degree of
soakage of the dressings
Outcomes Primary outcomes:
(1) Time to a clean wound bed - changes evaluated using specific variables; degree of
erythema; degree of pus and debris; oedema; necrosis; granulation tissue. The results for
each variable were assessed subjectively and presented individually
Degree of erythema (reported using a 0 to 3 degree table): no significant difference
reported (2 wounds in group A and 2 in group B did not have any erythema and were
excluded from the evaluation of this variable)
Oedema (reported using a 0 to 3 degree table): no significant difference (2 wounds
in group A and 2 in group B did not have any oedema and were excluded from the
evaluation)
Necrosis (reported as a percentage of the total area of thewound): no significant difference
(4 wounds in group A and 10 in group B did not exhibit any necrotic material and were
excluded from the evaluation)
Pus and debris (reported as a percentage of the total area of the wound): (1 wound in
group B did not have any pus or debris and was excluded from the evaluation)
No significant difference between the days of treatment or cleaning of the wounds.
However, the trial also reported a further division of group A and B for evaluation of
this variable, but it was unclear as to when this division was made and the handling
and reporting of the data was unclear, subjective and the groups were not comparable at
baseline. So while the subgroup of group A showed a higher degree of improvement in
the removal of pus and debris and this was reported as significant (P < 0.05, Student’s t-
test) the poor handling and subjective nature of the data makes this outcome unreliable.
The subgroup of group B did not demonstrate a significant difference
Granulation tissue:
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Michiels 1990 (Continued)
Mean time to a clean wound bed (SD not reported):
(A) mean 6.5 days
(B) mean 5.2 days
No significant difference (1 wound in group A and 2 in Group B did not have any
granulation tissue by the end of the trial and were excluded from the evaluation)
(2) Time to complete healing: not reported
Secondary outcomes:
(1) Patient satisfaction: not reported
(2) Rate of infection: not reported
(3) Quality of life: not reported
(4) Length of hospital stay: not reported
(5) Cost-effectiveness: not reported
(6) Adverse events: 1 patient in group B had an allergic reaction with oedema and
erythema after 10 days and the treatment was discontinued
Notes The development and testing of the comparison tables was not reported, therefore it is
not possible to determine the reliability and validity of these tables. While the mean days
for granulation tissue was reported, no other data or statistics were presented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients were allotted to one or other of
the preparations according to a randomisation list”
(p284)
Allocation concealment (selection bias) Unclear risk No details given about allocation concealment
Blinding (performance bias and detection
bias)
Participants and personnel
Unclear risk Participants - blinding not stated but blinding un-
likely to influence outcome
Personnel - blinding not stated but unlikely to be
achievable due to different properties (application of
paste versus soaked dressings). Lack of blinding un-
likely to influence results
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk Outcome assessor - blinding not stated, p284 states
that the “status of the wound was recorded each day
by the same doctor when the dressing was changed”
but no further detail is given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of the 5 criteria to be reported on (granulation, pus
and debris, erythema, oedema and necrosis) data are
included within report on all 5 with missing data ac-
counted for (for example within ’necrosis’ 4 patients
in one arm had no necrosis at the start or during so
not reported)
One patient in the control group exhibited an aller-
gic reaction to treatment therefore treatment was dis-
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continued (p288); it is not clear how this withdrawal
was dealt with in the data presented
Selective reporting (reporting bias) Low risk No study protocol available but expected outcomes
reported
States that “aim of study was to assess and compare
the clinical effects of dextranomer paste and a con-
trol treatment with polyvinylpyrrolidone (PVP) in a
trial of patients with infected post-operative wounds.
All variables dealing with cleansing, inflammation re-
ducing effect, and different signs of ongoing healing
were studied” (p284). Reporting of granulation, pus









Age: 26 to 86 years
Patients with infected laparotomy wounds, a minimum of 7 cm, requiring opening and
drainage
Inclusion criteria: wound infection following laparotomy surgery; operations included:
appendicectomy, bowel surgery, cholecystectomy, hysterectomy, repair of ventral hernia,
wound infection which necessitated opening and drainage of the wound
Minimum length of wound 7 cm
Maximum depth of wound 7 cm
Exclusion criteria: patients with burst abdomen, stoma or fistula in the vicinity of the
wounds, because this increased the risk of continuous wound contamination
Interventions A and B: initial drainage and removal of necrotic tissue method of removal not stated
All wounds dressed with saline dressings to secure haemostasis
(A) Twice-daily dressings, necrotic tissue removed; dressing soaked in 20 ml solution
(streptokinase/streptodornase) applied; solution provided by hospital pharmacy
(B) Twice-daily dressings, necrotic tissue removed; dressing soaked in 20 ml solution
applied; solution provided by hospital pharmacy (saline)
Outcomes Primary outcome: mean time to clean wound bed and closure by secondary suture:
(A) 5.00 days (SD = 2.16)
(B) 13.45 days (SD = 6.77)
Statistically significant (P < 0.05, both Student’s t-test and Mann-Whitney U-test)
Secondary outcomes:
(1) Patient satisfaction: neither group of patients complained of significant wound dis-
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Poulson 1983 (Continued)
comfort; no data or statistics presented
(2) Rate of infection: not reported
(3) Quality of life: not reported
(4) Length of hospital stay (median):
(A) 2.2 days less than group B
(B) Not reported
(5) Cost-effectiveness: not reported
(6) Adverse events: 3 patients were excluded from the evaluation for non completion
of the treatment; in group A 1 patient died of a pulmonary embolism and the other
required further surgery for intra-abdominal sepsis; 1 patient in group B was withdrawn
as a result of abdominal dehiscence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Pharmacy undertook the randomization” (p245)
, however no details are given regarding how this
randomisation was done
Allocation concealment (selection bias) Low risk Pharmacy prepared the solutions (20 ml Varidase or
20 ml saline)
Blinding (performance bias and detection
bias)
Participants and personnel
Unclear risk Not explicitly stated and therefore judged as unclear.
However, it would be highly unlikely that partici-
pants and personnel would have been able to tell
which solution was being applied as both ampoules
contained 20 ml of clear solution, so unlikely to
influence results. On p246 the authors state “only
when the code was broken 11 patients were found
to have saline and 7 had Varidase”
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk Not explicitly stated and therefore judged as unclear.
However, it would be highly unlikely that outcome
assessors would have been able to tell which solution
was being applied as both ampoules contained 20
ml of clear solution, so unlikely to influence results.
On p246 the authors state “only when the code was
broken 11 patients were found to have saline and 7
had Varidase”
Incomplete outcome data (attrition bias)
All outcomes
High risk From the 21 originally recruited, 3 were withdrawn:
2 from the placebo group and one from the Vari-
dase group. These 3 were excluded from the results
presented and therefore no ITT analysis was under-
taken. Rationales were given for the withdrawal
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Selective reporting (reporting bias) Unclear risk No study protocol available
The stated aim of the trial was “to show, by means of
a prospective clinical trial with randomised double
blind procedure if Varidase is superior to conven-
tionalmanagement of infected laparotomywounds”
(p245). However, they do not state what constitutes
’superior’ and how this would be measured. The
study reports number of days required for wound
dressing and number of days in hospital (within dis-
cussion section). Size of wound and type of bacterial
growth recorded at the start of the trial; this is not
reported on again within the results
Sondergaard 1982
Methods RCT
Setting: hospital inpatient and outpatient, Denmark
Participants n = 28 started the trial and 22 completed the trial
(A) 10
(B) 12
Numbers of men and women not reported
Participants ages not reported
Consent was not reported but patients were provided with oral and written objectives
of the study
Study was in accordance with the Helsinki declaration, 1975
Inclusion criteria: patients with suppurating infected surgical wounds involving subcu-
taneous tissue
Exclusion criteria: patients prescribed systemic steroid therapy; patients receiving another
local wound intervention; patients with substantial wound revision and if there was
peritoneal communication
Interventions A microbiological swab was taken from the bottom of each wound at the start of the
trial and on every 7th day until the wound was clean; this was to document the bacterial
flora to register any favourable influences of the dressings
(A) Wound irrigated with saline; dextranomer beads made into a paste and applied to
the wound; covered with a sterile compress; dressing changed at least daily and before it
became fully saturated
(B) Dressing soaked in 0.1% chloramine solution; covered with a sterile compress;
changed once daily and 2 or 3 times if saturated; dressings changed by senior registrars;
trial authors undertook assessment of the wounds
Outcomes Primary outcomes:
(1) Time to clean wound bed (reported as the median: mean, SD or SEM not reported
for any of the results):
(A) 6 days
(B) 5 days
(2) Time until the wound was clinically assessed as ready for outpatient treatment (me-
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(3) Time to wound healing (median):
(A) 27 days
(B) 20 days
Observed results were compared and assessed using the Mann-Whitney U-test; no sig-
nificant difference reported; detailed data and statistics not included
Secondary outcomes:
(1) Patient satisfaction: dressing changes were less painful in group A; no data or statistics
presented
(2) Rate of infection: not reported; results of microbiological wound swabs not reported
(3) Quality of life: not reported
(4) Length of hospital stay: not reported
(5) Cost-effectiveness:
(A) Approximately 123 Danish Kroner per dressing change
(B) Approximately 1.50 Danish Kroner per dressing change
Cost analysis not presented
(6) Adverse events: 4 patients excluded from group A: 2 patients died, cause of death
not reported; 1 had peritoneal communication; in 1 the wound was too undermined for
application of the paste; 2 excluded from group B: 1 had heavy growth of bacteria and
the dressing was changed to acetic alumina; 1 had a total wound rupture
Notes The trial authors did observe more granulation tissue; less irritation and less pain on
dressing changes with the dextranomer dressing. Blinding of assessors (trial authors) is
not reported. The original paper was in German and the data were extracted after being
translated into English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Although the trial reports that the patients
were allocated by a “random sequence gen-
erated in blocks of 4” (p1523) no further
information is given regarding the blocks
of 4. However, this is judged to be adequate
sequence generation
Allocation concealment (selection bias) Low risk “...sealed, numbered envelopes” (p1523) is
reported to conceal allocation, however it is
not stated if these envelopes were opaque.
However, this is judged to be adequate al-
location concealment
Blinding (performance bias and detection
bias)
Participants and personnel
Unclear risk It is not stated if the participants were
blinded however this would be unlikely to
influence findings. It is not stated if the per-
sonnel involved in redressing the wounds
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(senior registrars) were blinded or not
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk It is unclear from the trial if the assessors
(the study authors) were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk A total of 6 patients were excluded from the
study (2 from the chloramine and 4 from
theDebrisan), a rationale for the exclusions
is given and exclusions are mentioned in
the presented in results tables. It is not clear
if these were also excluded from the final
analysis. Also, the dropout rate was 21% (>
10%) and hence judged to be unacceptable
Selective reporting (reporting bias) Unclear risk No study protocol is available. No study
aims or outcomes are stated in the paper.
Results reported include: number of days
from start of treatment to a clean wound;
number of days until wound assessed as
ready for outpatient treatment; number of
days until wound healed. It is apparent that
the intention was also to examine the num-
ber of daily wound dressing changes re-




Setting: hospital and outpatient clinic, UK
Participants n = 50
(A) 25
(B) 25
Numbers of men and women not reported
Mean age (years):
(A) 44.48, SD 5.17
(B) 49.64, SD 4.57
Patients with surgical wound breakdown
Consent not reported
Inclusion criteria: patients undergoing surgery for perforated or gangrenous appendix,
where the wound was left open from the muscle layer outwards; patients with surgical
wound breakdown postoperatively
No exclusion criteria listed
Interventions Each wound was measured at the start of the trial:
Mean length (cm):
(A) 5.53, SD 0.55
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(B) 6.57, SD 0.89
Mean breadth (cm):
(A) 2.25, SD 0.33
(B) 2.48, SD 0.32
Mean depth (cm):
(A) 1.80, SD 0.20
(B) 2.24, SD 0.29
Mean volume (ml):
(A) 4.92, SD 1.15
(B) 6.37, SD 1.30
Individual wounds were photographed
All wounds were initially treated with gauze packing for the first 48 hours
(A) Dextranomer beads applied twice-daily: reduced to once a day when the discharge
reduced
(B) Silastic foam dressing applied, and this was removed and cleaned twice a day; reduced
to once a day with reduction in the discharge
All wounds were reviewed on 1st, 3rd and 7th days and then weekly. Patients discharged
home had their wounds reviewed weekly
The review included: photograph, measurement of the wound, review of erythema,
oedema, rash, odour and slough
Comfort of the dressing was assessed by questioning the patient
Pain was graded using an ordinal scale (0 = no pain to 3 = severe pain)
Outcomes Primary outcomes:
(1) Time to disappearance of erythema, oedema and slough: similar in group A and
group B; data and statistics not reported
(2) Mean time to complete healing (days):
(A) 40.92, SD 3.98
(B) 36.96, SD 3.18
Results subjected to analysis using the Student’s t-test
Secondary outcomes:
(1) Patient satisfaction: mean days until pain free dressings
(A) 5.32, SD 0.55 days
(B) 5.64, SD 0.45 days
Results subjected to analysis using the Student’s t-test
Wound pain reported as similar for both groups
(2) Rate of infection: not reported
(3) Quality of life: not reported
(4) Length of hospital stay: not reported
(4) Cost-effectiveness: authors quoted the costs as calculated in a previous study (Goode
1979):
(A) Approximately £3.40 per day
(B) Approximately £0.75 per week; no data or statistical evidence reported
(6) Adverse events: not reported
Notes An ordinal scale is used to assess the pain at dressing changes. This may result in skewed
data, so a non parametric Mann-Whitney U-test may have been more appropriate than
the Student’s t-test. Also there was a methodological flaw in the analysis of the data
and time to complete healing and time to a pain-free wound, which should have been
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expressed as a hazard ratio and not as continuous data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were allocated to receive either
Debrisan or Silastic foam elastomer by
means of a random card system” (p33).Not
clear if the cards were randomised. How-
ever, the method used for generating the
randomisation sequence for the cards was
not reported. Hence, it was judged to be
unclear
Allocation concealment (selection bias) Unclear risk Allocation concealment not stated
Blinding (performance bias and detection
bias)
Participants and personnel
Unclear risk It is not reported if participants were
blinded to treatment, however blinding
would be unlikely to affect results. Blinding
or not of personnel to treatment is not re-
ported, however due to the different prop-
erties of the dressings this would be un-
achievable
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk Limited information given within the pa-
per: “wounds were reviewed” (p33) but it
is not stated by whom and if they were
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up reported, 50 patients
completed the trial (25 in each arm)
Selective reporting (reporting bias) Low risk No study protocol is available but appro-
priate study outcomes reported
The aim of the trial was to “compare the
efficacy of these two dressings in surgical
wounds that have either broken down or
have been left open postoperatively” (p33)
. It is not stated how “efficacy” will be mea-
sured at the outset. Time to heal and time
to pain-free are reported within the trial;
presence of erythema, odour, slough and
rash were also reported
A = intervention group
B = control group
ITT = intention-to-treat
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RCT = randomised controlled trial
SD = standard deviation
SEM = standard error of the mean
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allie 2004 Non-randomised retrospective method
Bethell 2003 Literature review, not a research study
Cannavo 1998 RCT: comparison of alginate with gauze dressings for healing of surgical wounds, not of debridement
Capasso 2003 Non-experimental retrospective chart review
Cohn 2004 Comparison of hydrofibre to wet to dry dressings for healing rates of surgical wounds, not of debridement
De Feo 2001 Retrospective chart review of wound infections over 20 years
De Feo 2003 Retrospective non-randomised study
Doughty 2005 Management of surgical wound dehiscence and not a research paper
Douville 2004 Retrospective review of managing sternal wound complications
Edwards 1967 Clean surgical wound healing by primary intention - no debridement required
Foster 2000 Abscess wounds
Gliantsev 1996 In vitro study
Gottrup 2005 A review, not RCT
Granick 2006 Retrospective study of patients records: debridement of a range of wounds, including pressure ulcers, trauma
wounds and surgical wound complications
Guest 2005 Not RCT: models used to estimate the cost of 2 dressings
Kuleshov 1992 Not RCT: chronic wounds
Moore 2000 Included abscesses; did not measure debridement
Moore 2001 Systematic review
Moues 2004 Wounds treated prior to surgical closure
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Mulder 1995 Non-randomised study; debridement of chronic wounds
Rand 1998 Compared methods of wound closure for dehiscence, rather than debridement methods
Soul 1978 Not RCT: study included a range of wounds including pressure ulcers
Tolstykh 1987 Not RCT: no randomisation method identified
Williams 1995 Abscess wounds
Zeitani 2004 Not RCT: controlled study
RCT = randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 13 June 2013.
Date Event Description
13 June 2013 New citation required but conclusions have not changed No new studies identified for inclusion. The conclusions
remain the same
13 June 2013 New search has been performed Third update, new search.
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 3, 2008
Date Event Description
13 April 2011 New citation required but conclusions have not
changed
New lead author and contact person
13 April 2011 New search has been performed Second update, new search, no new studies included.
Risk of bias assessment completed on all included stud-
ies. The conclusions remain unchanged
12 January 2011 New search has been performed First update, new searches, no new studies identified,
conclusions remain unchanged
17 February 2010 Amended Contact details updated.
24 April 2008 Amended Converted to new review format.
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